Heavily pre-treated CD19+ B-cell malignancies (NHL, CLL, ALL); median 3–11 prior lines; often ineligible or high-risk for ASCT or autologous CAR-T. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.